Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-06
1999-01-05
Ulm, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
435 691, 530350, 536 234, A01N 3718, C07K 14705
Patent
active
058562974
ABSTRACT:
Human complement receptor type 1 (CR1). Nucleic acid molecules encoding full-length CR1 protein and fragments thereof having complement regulatory activity are described, as well as recombinant CR1 protein and polypeptides, vectors for their expression, and cell lines expressing or bearing DNA molecules encoding such proteins and polypeptides, including a soluble CR1 polypeptide consisting of the extracellular 30 short consensus repeat domains of the mature CR1 protein. The nucleic acids and polypeptides described are useful in diagnosis and treatment of disorders involving complement activity and inflammation. Compositions useful in therapeutic applications are also disclosed.
REFERENCES:
patent: 4285932 (1981-08-01), Smith et al.
patent: 4642284 (1987-02-01), Cooper et al.
patent: 4672044 (1987-06-01), Schreiber et al.
patent: 4883784 (1989-11-01), Kaneko
Andreatta et al. Chemical Abstracts vol.: 94(21), p. 303, Abstract 170110u; for Enzyme Inhibitors, Proc. Meet., Brodbeck, U. (Ed), Verlag Chem. pp. 261-272 (1980).
Atkinson and Jones, J. Clin. Invest. 74:1649-1657 (1984).
Chung and Reid, Bioscience Reports 5:855-865 (1985).
Chung et al., Biochem J. 230:133-141 (1985).
Dahlback et al., Proc. Natl. Acad. Sci. U.S.A. 80:3461-3465 (1983).
Darnell et al., in Molecular Cell Biology second edition. 500-504 (W.H. Freeman and Co., New York, 1990).
Dykman et al., Proc. Natl. Acad. Sci. U.S.A. 80:1698-1702 (1983).
Fasman and Gilbert, T.I.B.S. 15:89-92 (1990).
Fearon, Proc. Natl. Acad. Sci. U.S.A. 76:5867-5871 (1979).
Frank, New Eng. J. Med. 316:1525-1530 (1987).
Fries et al., J. Immunol. 135:2673-2679 (1985).
Glover et al., Mol. Immunol. 25:1261-1267 (1988).
Hewick et al., J. Biol. Chem. 256:7990-7997 (1981).
Hiraki et al., J. Immunol. 136:4291-4296 (1986).
Holers et al., Proc. Natl. Acad. Sci. U.S.A. 84:2459-2463 (1987).
Hourcade et al., Abstracts: XII Int. Complement Workshop in Complement, pp. 171-172 Abstract 128 (1987).
Hourcade et al., Abstracts: XII Int. Complement Workshop in Complement, p. 172 Abstract 129 (1987).
Hourcade et al., J. Exp. Med. 168:1255-1270 (1988).
Iida and Nussenzweig, J. Exp. Med. 153:1138-1150 (1981).
Iida et al., J. Exp. Med. 155:1427-1438 (1982).
Klein et al., Biochimica et Biophysica Acta 815:468-476 (1985).
Klickstein et al., J. Exp. Med. 165:1095-1112 (1987).
Klickstein et al., Abstracts: XII Int. Complement Workshop in Complement, p. 180 Abstract 149 (1987).
Klickstein et al., J. Exp. Med. 168:1699-1717 (1988).
Kristensen et al., Biochem. 26:4668-4674 (1987).
Krych et al., F.A.S.E.B. J. 3:A368 Abstract 824 (1989).
Kumar et al., Biochem. 28:4040-4046 (1989).
Kyte and Doolittle, J. Mol. Biol. 157:105-132 (1982).
Maillet et al., Mol. Immunol. 25(9):917-923 (1988).
Matzner et al., Chemical Abstracts vol. 106(1), p 353, Abstract 3626b,(1987), for J. Cell. Physiol. 129:215-220 (1986).
Medof et al., Ann. N.Y. Acad. Sci. 421:299-306 (1983).
Schasteen et al., Mol. Immunol. 25:1269-1275 (1988).
Seya et al., J. Immunol. 135:2661-2667 (1985).
Sim, Biochem. J. 232:883-889 (1985).
Weis et al., Proc. Natl. Acad. Sci. U.S.A. 83:5639-5643 (1986).
Weis et al., J. Immunol. 138:312-315 (1987).
Weisman et al., Science 249:146-151 (1990).
Wilson et al., Immunol. Res. 6:192-209 (1987).
Wong and Fearon, J. Immunol. 134:4048-4056 (1985).
Wong et al., J. Exp. Med. 164:1531-1546 (1986).
Wong et al., J. Immunol. Meth. 82:303-313 (1985).
Wong et al., Proc. Natl. Acad. Sci. U.S.A, 82:7711-7715 (1985).
Yoon and Fearon, J. Immunol. 134:3332-3338 (1985).
Flickstein et al. (1988) J. Exp. Med. V168:1699-1717.
Ngo et al. 1994 In: The Protein Folding Problem and Tertiary Structure Prediction. Merz et al Eds Birkhaulser Boston, pp. 433 and 492-495.
Carson Gerald R.
Concino Michael F.
Fearon Douglas T.
Ip Stephen H.
Klickstein Lloyd B.
Brigham & Women's Hospital
T Cell Sciences, Inc.
The Johns Hopkins University
Ulm John
Yankwich Leon R.
LandOfFree
Human C3b/C4b receptor (CR1) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human C3b/C4b receptor (CR1), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human C3b/C4b receptor (CR1) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-862332